The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...
"My life was hell": Man awarded £160,000 damages after Parkinson's drug turned him into gay sex and gambling addict ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a settlement of up to $2.2bn (€2.01bn) to end tens of thousands of lawsuits in ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...